At the beginning of 2017, LMC Diabetes & Endocrinology published a paper in the journal of Health and Quality of Life Outcomes about our novel tool – LMC Skills, Confidence & Preparedness Index (SCPI). SCPI is a new tool that can be used to assess...
LMC’s telemedicine service is dedicated to the provision of medical consultation and follow-up services for Diabetes & Endocrine conditions to individuals over the age of 18 living in the various LHIN’s. We have recently begun accepting referrals from...
Sanofi announced on July 28th that the U.S. Food and Drug Administration (FDA) approved AdlyxinTM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. “The...
